BioNote
바이오노트 · 377740
Health Care Pharmaceuticals · KOSPI
Market cap US$352.2M (₩486B)
Overview
BioNote makes rapid diagnostic test kits and reagents used to detect diseases in animals, relying on its own technology for producing recombinant antigens and antibodies, the biological building blocks that make diagnostic tests work.
Its products are supplied to distributors and affiliated partners in multiple countries. Listed on KOSPI, Korea's main stock exchange, the company is also expanding its core biological materials, antigens, antibodies, and enzymes, into the supply chain for human in-vitro diagnostic (IVD) reagents, broadening beyond its veterinary roots.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$65.3M
- FY2024US$74.5M
- FY2025US$85.7M
Operating profit
- FY2023−US$34.1M
- FY2024US$8.9M
- FY2025US$12.1M
Net income
- FY2023−US$14.9M
- FY2024US$40M
- FY2025−US$63.4M
Key ratios (FY2025)
Price charts coming soon
Interactive price history isn't here yet. Would you use it?